The dog-days of summer produced just a handful of mergers and acquisitions in the medtech sector and no blockbuster deals. However, several companies made smaller deals for innovative products in a range of sectors including IVDs, cardiovascular devices, and ophthalmology.
There were only 13 medtech deals in August, according to Medtech Insight's Mergers & Acqusitions Tracker, and there were no deals worth more than $500m. But the few deals that did go through represent a broad spectrum of industry subsectors and innovative technologies.
The list of medtech deals for August includes eight for which the terms were not disclosed by the companies, four worth under one-hundred million dollars and just one that surpassed...
TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.
The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.
Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.
